Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

Video

Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.

Background

  • mTOR pathway activation is common in PEComa.
  • PEComa are associated with alterations of TSC1 or TSC2, which are negative regulators of the mTOR signaling pathway.1
  • Nab-sirolimus is a­­n mTOR inhibitor (mTORi) with significantly higher anti-tumor activity, significantly higher intratumoral drug accumulation, and significantly higher mTOR target (pS6 and p4EBP1) suppression in preclinical models.

Methods

  • Sample Size: Overall response rate (ORR) of ~30% in 30 evaluable patients to exclude the lower bound of the 95% CI of 14.7%
  • Efficacy Evaluable Patients: Must receive 1 dose or more of nab-sirolimus; must have centrally confirmed PEComa
  • Primary End point: ORR by independent radiology review (RECIST v1.1)
    • CT/MRI every 6 weeks for the first year, every 12 weeks thereafter
  • Secondary End points:
    • Duration of response (DOR), progression-free survival (PFS) at 6 months, median PFS, median overall survival
    • Safety
  • Key Exploratory End points: Investigator response assessment
    • Biomarker were mutational analysis (NGS, IHC, FISH)
  • Baseline Demographics, Characteristics, and Disposition:
    • Median follow-up was 22 months (range 1, 58)
    • Thirty of thirty-four patients discontinued treatment; the main reason was PD (59%). Other reasons included adverse event (AE), surgery, withdrew consent, and death
    • Four patients have ongoing treatment (all responders)
    • Six patients are in post-treatment, on-study follow-up for survival

Results

  • Two patients converted from a partial response (PR) to a complete response (CR) after 11 months and 34 months of treatment, respectively
  • Median DOR has not been reached, 50% of patients had a DOR of more than 36.1 months (range 5.6, 55.5+ months)
  • No grade 4 or 5 treatment-related AEs
  • No unexpected AEs or new safety signals
  • Pneumonitis in 7 out of 34 (21%) patients was grade (G)1/G2 only
  • Discontinuation due to AEs: 2 out of 34 (6%) patients (G2 anemia and G1 cystitis)
  • Treatment-related Serious Adverse Events were:
    • Dehydration in 6% of patients and 3% each of acute kidney injury, acute coronary syndrome, abdominal pain, diarrhea, edema, enteritis, and pancytopenia
      • All recovered / resolved

Conclusions

  • This registrational trial met its primary end point; the independently assessed confirmed ORR was 39% (95% CI 22%-58%), 2 CRs and 10 PRs, with durable responses and acceptable safety profile
  • Median DOR has not been reached; 50% of patients had a response exceeding 36 or more months (range: 5.6, 55.5+)
  • Disease control (CR/PR/stable disease [SD] ≥ 12 weeks) was achieved in 71% of patients
  • No new safety signals were observed despite relatively high doses of nab-sirolimus compared with other mTORis
  • Mutational Analysis Versus Response:
    • TSC2 mutations: 89% (8/9) of patients had confirmed ORR (1/9 had an unconfirmed response)
    • Responses also occurred in some patients with TSC1 or no TSC1/TSC2 or unknown mutational status.
    • This first prospective study in advanced malignant PEComa suggests that nab-sirolimus is active in a rare and aggressive sarcoma for which there are no approved therapies.
    • A tumor-agnostic study is planned for patients with pathogenic inactivating TSC1 or TSC2 alterations.

1. Wagner A, Ravi V, Riedel RF, et al. Final Analysis from AMPECT, an open-label phase 2 registration trial of nab-sirolimus for patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Abstract presented at: 2021 Connective Tissue Oncology Society, November, 10-13. Abstract #108747

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Yelena Y. Janjigian, MD, an expert on gastrointestinal cancer
Guru P. Sonpavde, MD, an expert on urothelial carcinoma
Related Content